Q&As

Dr Feuerstein chaired the guideline panel that developed the American Gastroenterological Association's new guidelines on managing ulcerative colitis. He sat down with Gastroenterology Learning Network to answer a few questions.
Patients with inflammatory bowel disease are at increased risk for contracting vaccine-preventable diseases, yet often have lower rates of immunization than the general population. There are ways to improve these rates and protect patients, according to Freddy Caldera, DO, from the University of Wisconsin.
About 25% of patients with one autoimmune disease are likely to develop another autoimmune condition. Dr Bonder, from Beth Israel Deaconess Medical Center in Boston, talks about the importance of screening patients with primary biliary cholangitis for rheumatoid arthritis, Sjogren syndrome, and other conditions.
Researchers conducted a study of genomic data to clarify the relationships among nonalcoholic fatty liver disease, type 2 diabetes, and obesity. Lead author Wanqing Liu, PhD, answered our questions about the study.
Karen N. Zaghiyan, MD, answers our questions about her session at the Advances in Inflammatory Bowel Disease Regionals 2020.
The American Gastroenterological Association has recently published a clinical practice update on functional heartburn. Lead author Ronnie Fass, MD, answered our questions about the update.
In a new study, researchers sought to clarify how the gut microbe may influence chronic gastrointestinal disease. The coauthors Michael C. Hoaglin, MD and Melissa Agnello, PhD answered our questions about their research.
The relationship between climate change and human health has not been thoroughly explored. Desmond Leddin, MB, MSc, has taken an interest in studying this relationship. In this Q&A, he answers our questions about his latest article on the topic.
Ikuo Hirano, MD, the chair of the writing committee, answers our questions about the new ACG/JTF guidelines on the management of eosinophilic esophagitis.
Joshua Z. Goldenberg, ND, answered our questions about his team’s study aimed to assess the efficacy and safety of biofeedback-based interventions for treating irritable bowel syndrome among adults and children.